Shares of BTP “Breakthrough Tech” portfolio holding Novo Nordisk (NVO) rallied on 4/28/16. The company announced “top line” results from its global Phase 3a trial of semaglutide, noting that the medication “significantly” reduces the risk of major cardiovascular events.

Semaglutide is used in the treatment of type II diabetes improving control of blood sugar with low risk of inducing dangerous blood sugar levels and also induces weight loss by decreasing appetite.  The study reached its endpoint of reducing cardiac deaths, myocardial infarctions or non fatal strokes.  Novo expects to submit semaglutide for approval in the U.S. and Europe in 2016.

Novo is the world leader in treatment for diabetes, and reports earnings on 4/29/16 that I will review in an upcoming issue of Breakthrough Tech Weekly.

Buy Novo Nordisk (NVO) up to $59. Risk-averse investors should consider placing a Stop Loss order beneath it at $49.

Disclosure: I own shares in Novo Nordisk.